Codiak – based on research at Gothenburg and MD Anderson Cancer Center – has succeeded in going public after previously cancelling plans.

US-based exosome therapeutics developer Codiak Biosciences has gone public in an $82.5m initial public offering offering an exit to University of Texas System. The company is issuing 5.5 million shares on the Nasdaq Global Market priced at $15 each, in the middle of the offering’s $14 to $16 range. It had previously filed for an…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.